TO THE EDITOR
In their comment, 1 Schuster et al report on two children suffering from acute myeloid leukemia (AML) relapse after allogeneic stem cell transplantation (SCT) , that were treated according to a protocol published in a recent issue of Leukemia.
2 Both patients had an unfavorable cytogenetic aberration and had shown delayed response to initial chemotherapy, indicating high-risk disease. SCT from an HLAidentical sibling had been applied as consolidation therapy. No Graft-versus-Host disease (GvHD) occurred, and both patients achieved complete hematological remission (CHR) and negativity for minimal residual disease markers. However, cytogenetic, respectively molecular relapse was detected before day þ 100, followed by hematological relapse at 6 and 9 months from transplant. Intensive reinduction chemotherapy was given, and adoptive immunotherapy, using mobilized donor peripheral blood stem cells (PBSC), GM-CSF, IL2 and transfusion of unstimulated donor lymphocytes, was applied. No acute GvHD occurred after PBSC. One patient relapsed again at 15 months from treatment and received a second transplant from another donor, whereas the other patient achieved a remission of 42 years.
The two cases presented here seem to confirm the data of our pilot study, in that the sequence of cytoreductive chemotherapy, transfusion of donor PBSC without further conditioning or immunosuppression, and immunomodulation by systemic application of cytokines is a feasible and effective approach to the treatment of relapsed AML post-transplant. A Graft-versusLeukemia effect is suggested by the duration of the achieved remission, that was considerably longer after adoptive immunotherapy than after initial HSC in both cases.
In their discussion the authors raise several important issues related to the management of AML relapse after SCT. First, the intensity of cytoreductive chemotherapy prior to donor cell transfusion is discussed. In our pilot study, low-dose AraC (LdAraC) has been used for initial control of leukemic proliferation to avoid hospitalization and to minimize toxicity. Intensive chemotherapy was given in case of progressive disease only, since high treatment-related morbidity and mortality (TRM) had been reported in adults after aggressive treatment, in particular in patients with an early post-transplant relapse.
3
Reinduction of complete remission was not intended in our study, given the limited efficacy of chemotherapy-based approaches in post-transplant relapse. In addition to cytoreduction, LdAraC has been reported to have effects with respect to promotion of an allogeneic immune reaction 4 and to induction of leukemic cell differentiation.
5 Disease control by LdAraC could be achieved in 45% of our cases, allowing 9/24 patients to be completely treated as outpatients before PBSC transfusion.
Response to LdAraC was highly predictive for achieving CHR and for survival after adoptive immunotherapy. Aggressive reinduction chemotherapy was required in 13 patients with rapidly progressive disease. It was associated with increased TRM in this group. However, this aspect may be of less importance in the pediatric setting, thereby allowing a more aggressive reduction of tumor burden in children, as it was used in the presented cases. In general, the role of induction of CHR before adoptive immunotherapy remains to be defined. Patients receiving donor cells in CHR might represent a positive selection of less aggressive disease. In a retrospective study by the EBMT, the use of chemotherapy before DLT was not associated with better outcome.
6
The possibility of a second transplant represents an alternative strategy for the management of post-transplant relapse. In particular, using an alternative donor seems attractive, with the first one having obviously failed to apply a sufficient GvL effect. However, at least in adults, high TRM has complicated this approach, when standard conditioning was used.
7 Even in the pediatric study cited by Schuster and colleagues, 8 TRM was 29% in children receiving a second graft after an allogeneic first SCT. Recently, second transplants following reduced intensity conditionings have been introduced. 9 Although it is too early to definitely decide on the efficacy of this approach, first data suggest only moderate effects.
10
Finally, Schuster et al speculate on a role of NG2 within the GvL reaction. NG2 is a cell-surface antigen expressed in the majority of AML cases with a cytogenetic abnormality at the 11q23 locus, which is associated with a dismal outcome in several studies. In general, no target antigen has been identified that might allow for a specific immunotherapy for AML. In contrast, bcr/abl and RARA fusion peptides, peptides derived from proteinase 3, and the WT1 peptide are under investigation as leukemia-associated targets (summarized in Kolb et al 6 ); polymorphic minor histocompatibility antigens represent an alternative group of targets for allogeneic immune reactions. Further studies with respect to GvL mechansims are warranted, before we will be able to apply a targeted immunotherapy in a disease as heterogenous as AML. A family has recently been described in whom three members affected by acute myeloid leukaemia (AML) carried germline heterozygous mutations in CCAAT enhancer-binding proteinalpha (CEBPA), the gene encoding the granulocyte differentiation factor C/EBPa. 1 The transcription factor C/EBPa is a key regulator of early myeloid differentiation, regulating a number of granulocyte-specific genes and inducing granulocytic development of bipotential myeloid progenitors by activation of target gene promoters.
2 C/EBPa consists of N-terminal transactivating domains (TAD1 and TAD2) and a C-terminal basic and leucinezipper region necessary for specific DNA sequence binding and homo-or heterodimerization, respectively.
2 Here, we report the clinical and molecular features of a second family in which a germline mutation in CEPBA caused AML.
The family, in which four members had documented evidence of developing AML was originally reported in 1998 (Figure 1 ).
3
Briefly, individual III:1 presented at 34 years of age with AML. Individual IV:2 presented at age 25 years with AML M4 with eosinophilia with cytogenetic analysis revealing an abnormal clone 46XY,del(6)(q21) in 5/16 cells. Individual IV:4 presented at age 24 years with AML M1. No clonal cytogenetic abnormality was detected. Individual V:1 presented at age 4 years with AML M1. Cytogenetic analysis of individual V:1 at presentation was normal but on relapse the clonal abnormality 47,XY, þ 8 was observed, with clonal evolution to 47,XY, þ 8, þ 21 at subsequent relapse. Individuals IV:2 and V:1 remain well 18 and 14 years from original diagnosis of AML, respectively, despite experiencing one or more relapses. Individual IV:4 remains well in first remission 11 years from original diagnosis of AML. He has been shown to have a normal 46,XY karyotype. All members of the family (Figure 1 ) are white Caucasians and there is no evidence of consanguinity. We have previously excluded involvement of Fanconi, mutations in TP53 and RUNX1 and linkage to 16q21-23.2 as a cause of AML in the family.
3,4
Samples of mononuclear-cell-enriched peripheral blood samples were obtained at diagnosis from individuals IV:2 and IV:4. Peripheral blood samples for germline mutation analysis were obtained from III:2 and IV:3 and from individuals IV:2, IV:4 and V:1 during remission. DNA was extracted using a routine salt-precipitation methodology.
The complete coding sequence of CEBPA (referenced to GenBank accession Y11525) was screened in individuals III:2, IV2, IV:3, IV:4 and V:1 as a series of overlapping PCR fragments. PCR primers were designed by use of Primer 3 software (http://www.broad.mit.edu/cgi-bin/primer/primer3_www.cgi). All primer sequences and PCR conditions are available upon request. Amplified PCR products were purified (Qiagen Inc., Valencia, CA, USA) and bidirectionally sequenced using BigDye Terminator chemistry implemented on an ABI Prism 3100 sequencer. Sequences were aligned and compared to consensus Figure 1 Pedigree showing the autosomal dominant inheritance of AML. Blackened symbols denote affected individuals and asterisks indicate the individuals from whom tumour samples were available for sequencing.
